Staff Publications

Staff Publications

  • external user (warningwarning)
  • Log in as
  • language uk
  • About

    'Staff publications' is the digital repository of Wageningen University & Research

    'Staff publications' contains references to publications authored by Wageningen University staff from 1976 onward.

    Publications authored by the staff of the Research Institutes are available from 1995 onwards.

    Full text documents are added when available. The database is updated daily and currently holds about 240,000 items, of which 72,000 in open access.

    We have a manual that explains all the features 

Record number 559334
Title Chemotherapy and vitamin D supplement use are determinants of serum 25-hydroxyvitamin D levels during the first six months after colorectal cancer diagnosis
Author(s) Wesselink, Evertine; Bours, Martijn J.L.; Wilt, Johannes H.W. de; Aquarius, Michiel; Breukink, Stephanie O.; Hansson, Bibi; Keulen, Eric T.P.; Kok, Dieuwertje E.; Ouweland, Jody van den; Roekel, Eline H. van; Snellen, Merel; Winkels, Renate; Witkamp, Renger F.; Zutphen, Moniek van; Weijenberg, Matty P.; Kampman, Ellen; Duijnhoven, Fränzel J.B. van
Source Journal of Steroid Biochemistry and Molecular Biology 199 (2020). - ISSN 0960-0760
DOI https://doi.org/10.1016/j.jsbmb.2020.105577
Department(s) Nutrition and Disease
VLAG
Nutritional Biology and Health
Publication type Refereed Article in a scientific journal
Publication year 2020
Keyword(s) Changes over time - Colorectal cancer - Lifestyle and clinical determinants - Patients - serum 25(OH)D - Vitamin D
Abstract

Vitamin D metabolites, including 25-hydroxyvitamin D3 (25(OH)D3), may inhibit colorectal cancer (CRC) progression. Here we investigated cross-sectional and longitudinal associations of demographic, lifestyle and clinical characteristics with 25(OH)D3 serum concentrations in CRC patients at diagnosis and six months later. In 1201 newly-diagnosed stage I-III CRC patients, 25(OH)D3 levels were analysed twice. Multivariable linear regression was used to assess demographic, lifestyle and clinical determinants of 25(OH)D3 levels at diagnosis and six months later. Linear mixed models were used to assess characteristics associated with changes in 25(OH)D3 levels over time. Results of our study showed that vitamin D intake from diet or supplements, use of calcium supplements, BMI and disease stage were associated with 25(OH)D3 levels at both time points. Six months after diagnosis, gender and having received chemo- and/or radiotherapy were also associated with 25(OH)D3 levels. A stronger decrease in 25(OH)D3 levels was observed in patients who underwent chemotherapy, compared to surgery only (β-6.9 nmol/L 95 %CI -9.8; -4.0). Levels of 25(OH)D3 levels increased in patients using vitamin D supplements compared to non-users (β 4.0 nmol/L 95 %CI 1.2; 6.8). In conclusion, vitamin D supplement use and treatment appear to be important determinants of 25(OH)D3 levels during the first six months after CRC diagnosis, although the difference in 25(OH)D3 levels was minor. ClinicalTrials.gov Identifier: NCT03191110

Comments
There are no comments yet. You can post the first one!
Post a comment
 
Please log in to use this service. Login as Wageningen University & Research user or guest user in upper right hand corner of this page.